MediciNova Receives Notice of Allowance for Pending Patent Application Covering MN-029
October 06, 2013 at 23:19 PM EDT
MediciNova (Nasdaq: MNOV ) announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-029 (denibulin) di-hydrochloride. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than July 2032.
